Loading...
XCNQ
SONA
Market cap25mUSD
Oct 08, Last price  
0.32CAD
1D
-4.55%
1Q
6.78%
Jan 2017
950.00%
IPO
85.29%
Name

Sona Nanotech Inc

Chart & performance

D1W1MN
XCNQ:SONA chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
13.30%
Rev. gr., 5y
%
Revenues
0
3,674279,735262,62300000000000000000
Net income
-3m
L+20.21%
-248,861-1,112,000-1,485,000-8,336,000-674,000-696,000-4,844,000-584,082-2,021,853-840,048-3,639,850-2,282,222-5,272,000-2,942,000-6,272,000-10,768,000-2,361,000-2,500,000-2,704,000-3,250,345
CFO
-2m
L+0.07%
-172,979-799,599-1,156,865-530,555-385,535-398,797-721,283-386,734-404,941-54,407-277,607-116,287-1,391,441-1,362,799-4,054,643-3,813,340-1,805,403-1,260,455-1,959,710-1,960,994

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Based in Halifax, Canada, Sona Nanotech Inc. is a life sciences company focused on nanotechnology. It develops and commercializes gold nanorod solutions primarily for diagnostic applications. Their product portfolio includes the Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic test designed to detect the SARS-CoV-2 spike protein antigen in saliva from individuals suspected of having the virus. The company also offers Gemini and Omni gold nanorods, with the latter specifically engineered for medical uses, in addition to providing contract services. These versatile products are utilized in a wide array of applications, such as targeted drug delivery, environmental and food safety monitoring, cellular visualization, cancer therapy, liposuction treatments, and diagnostic tools for medical, consumer, military, and veterinary sectors.

Key people

David Regan
Chief Executive Officer · since 2020
Chief Financial Officer, Corporate Secretary · since 2012
Carman Giacomantonio
Chief Medical Officer · since 2024
Harold Megann
Director · since 2019
Wayne Myles
Director · since 2024
Len Pagliaro
Chief Scientific Officer, Director · since 2023
Neil Fraser
Independent Director · since 2022
John Lievonen
Independent Director · since 2020
Walter Strapps
Independent Director · since 2022
IPO date
Oct 04, 2018
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑102024‑102023‑102022‑102021‑102020‑102019‑102018‑102017‑102016‑10
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT